All In Biotech

Drug Trial Radar · NCT06190275

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Infusion (GT201) in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 12, 2024

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
Collaborators
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.

Conditions

  • HNSCC

Interventions

  • GT201 in combination with PD-1 inhibitorsBiological

    GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidience and severity of adverse events per CTCAE 5.0Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Ninth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.